On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago.
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.
From a technical perspective, Embecta Corp. (EMBC) is looking like an interesting pick, as it just reached a key level of support. EMBC recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Embecta Corp. (NASDAQ:EMBC ) Q3 2024 Earnings Conference Call August 9, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP & Head of IR Dev Kurdikar - President, CEO & Director Jake Elguicze - SVP & CFO Conference Call Participants Marie Thibault - BTIG Travis Steed - Bank of America Securities Kristen Stewart - CL King Michael Polark - Wolfe Research Operator Please stand by. Welcome ladies and gentlemen to the Fiscal Third Quarter 2024 Embecta Earnings Conference Call.
Embecta Corp. (EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago.
The White House recently confirmed increased tariffs on various Chinese goods. Investors and traders are on the lookout for stocks to benefit from China tariffs as the change could significantly impact many industries, including the U.S. automotive industry, electric vehicles (EVs) and others.